Chronic Pain With Opioid Tolerance — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for chronic pain with opioid tolerance. 297 active patents protecting 5 drugs from 5+ originators. First major cliff: 2032. Daily refresh.

5
Approved drugs
297
Active US patents
56/100
Avg vulnerability
$1.6B
Annual revenue covered

Originators in Chronic Pain With Opioid Tolerance

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Indivior 96 patents Purdue Pharma Lp 79 patents Johnson & Johnson (Janssen Pharmaceutica) 68 patents Purdue Pharma 40 patents Fresenius Kabi 14 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating chronic pain with opioid tolerance. Each bar = one year. Y-axis scaled to peak year (100 patents).

7
26
87
27
5
28
8
29
39
30
16
31
100
32
7
34
7
35
20
36
1
38

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Subutex
Buprenorphine Hydrochloride
 Indivior 96 62 $800M 2027-07-23
Subutex
BUPRENORPHINE
 Purdue Pharma Lp 79 71 $800M 2026-07-31
Duragesic
fentanyl
 Johnson & Johnson (Janssen Pharmaceutica) 68 51 — 2027-01-25
OxyContin
oxycodone
 Purdue Pharma 40 51 — 2028-10-09
Dilaudid-Hp
Hydromorphone Hydrochloride
 Fresenius Kabi 14 46 — 2032-04-23

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
8236755 Subutex method of use 88 2026-07-31
8236755 Subutex method of use 88 2026-07-31
8236755 Subutex method of use 88 2026-07-31
8236755 Subutex method of use 88 2026-07-31
8236755 Subutex method of use 88 2026-07-31
8236755 Subutex method of use 88 2026-07-31
8236755 Subutex method of use 88 2026-07-31
8236292 Subutex method of use 88 2027-01-10
8236292 Subutex method of use 88 2027-01-10
8236292 Subutex method of use 88 2027-01-10

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
8486972 Duragesic formulation 36 2030-04-27
8486972 Duragesic formulation 36 2030-04-27
8486972 Duragesic formulation 36 2030-04-27
8486972 Duragesic formulation 36 2030-04-27
8486972 Duragesic formulation 36 2030-04-27
8486972 Duragesic formulation 36 2030-04-27
8486972 Duragesic formulation 36 2030-04-27
9522188 Subutex formulation 42 2035-04-24
9522188 Subutex formulation 42 2035-04-24
9522188 Subutex formulation 42 2035-04-24

Related